Johnson & Johnson: A Safe Haven That's Quietly Becoming A Bit Overpriced (NYSE:JNJ)

In April 2025, I published my last article about Johnson & Johnson (NYSE: JNJ ), and I rated the stock as a 'Buy.' In the conclusion of my last article, I wrote:My analysis is focused on high-quality companies, that can outperform the market over the long-run due to a competitive advantage (economic moat) and high levels of defensibility. Focused on European and North American companies, but without constraints regarding market capitalization (from large cap to small cap companies).My academic background is ...